global Transient Ischemic Attack Market

Transient Ischemic Attack Comprehensive Study by End Users (Hospitals & Clinics, Diagnostic Centers, Research Laboratories), Age Group (0–18 years, 19–40 years, 41–60 years, 60+ years), Diagnosis Type (Imaging Techniques, Computed Tomography (Ct) Scan, Carotid Duplex Scanning, Magnetic Resonance Imaging, Echocardiography, Arteriography), Treatment (Medication {Anti-Platelet Drugs, Anticoagulants, Thrombolytic Agents}, Surgery, Angioplasty) Players and Region - Global Market Outlook to 2030

Transient Ischemic Attack Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 6.91%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Transient Ischemic Attack
Transient Ischemic Attack (TIA) is also known as transient ischemic stroke is also known as a mini-stroke. It is the same as a stroke, except that the symptoms last for a short amount of time due this it is often ignored. This is because of the blockage that temporary stops the blood getting to brain. The increasing population with unhealthier habits is leading rise in the number of heart stroke diseases globally. According to a guidelines, a patients experiencing Transient Ischemic Attack (TIA) should undergo head imaging within 24 hours of symptom onset, preferably with magnetic resonance imaging, including diffusion sequences. As per the sources, by end of 2030 the United States will account over 17.9 million deaths due to cardiovascular disorder and over 23.6 million deaths. The growing healthcare expenditure will drive the market growth in forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
CAGR6.91%


The competitive landscape in the Transient Ischemic Attack market is constantly evolving, driven by technological advancements, increasing awareness, and the need for cost-effective and accessible solutions. By collaborating across different sectors and focusing on personalized, preventative approaches, the healthcare community can improve outcomes for Transient Ischemic Attack patients and reduce the risk of future strokes. Analyst at AMA Research estimates that United States and European Players will contribute the maximum growth to Global Transient Ischemic Attack market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Abbott Laboratories (United States), Boston Scientific Corporation (United States), Cardinal Health, Inc. (United States), GE Healthcare (United States), Medtronic plc (Ireland), Merck & Co. Inc. (United States), Siemens Healthineers AG (Germany), LivaNova PLC (United Kingdom), Bayer AG (Germany), Cigna (United States), Novartis AG (United States) and Pfizer Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Daiichi Sankyo Co., Ltd. (Japan), electroCore, Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), Sanofi SA (France), Stryker Corporation (United States), Terumo Corporation (Japan) and Zocere, Inc. (Mexico).

Segmentation Overview
AMA Research has segmented the market of Global Transient Ischemic Attack market by and Region.



On the basis of geography, the market of Transient Ischemic Attack has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. Europe, on the other hand, stood as the second largest market due to the presence of key companies in the region and high technological advancement. If we see Market by End Users, the sub-segment i.e. Hospitals & Clinics will boost the Transient Ischemic Attack market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. 0–18 years will boost the Transient Ischemic Attack market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis Type, the sub-segment i.e. Imaging Techniques will boost the Transient Ischemic Attack market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment , the sub-segment i.e. Medication {Anti-Platelet Drugs, Anticoagulants, Thrombolytic Agents} will boost the Transient Ischemic Attack market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
New Advancements In Catheterization Devices and Telemedicine

Market Growth Drivers:
Rising Prevalence Of Transient Ischemic Attack In Young People Favorable Reimbursement Policies and Guide Wire Assisted Surgery In Elderly Population

Challenges:
Lack of Skilled Professional and Awareness

Restraints:
High Cost of Treatment

Opportunities:
Rising Consumer Expenditure on Health and Government Initiatives and Investment in Research & Development Activities

Market Leaders and their expansionary development strategies
In December 2023, BioSig Technologies partners with the University of California, San Francisco, to conduct clinical trials evaluating the effectiveness of BioSig One in TIA diagnosis and stroke prediction.
In October 2023, Abbott introduces the FreeStyle Libre 3 biosensor, providing continuous glucose monitoring and potentially aiding in stroke risk assessment for high-risk individuals.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Healthcare Service Providers, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and Contract Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By End Users
  • Hospitals & Clinics
  • Diagnostic Centers
  • Research Laboratories

By Age Group
  • 0–18 years
  • 19–40 years
  • 41–60 years
  • 60+ years

By Diagnosis Type
  • Imaging Techniques
  • Computed Tomography (Ct) Scan
  • Carotid Duplex Scanning
  • Magnetic Resonance Imaging
  • Echocardiography
  • Arteriography

By Treatment
  • Medication {Anti-Platelet Drugs, Anticoagulants, Thrombolytic Agents}
  • Surgery
  • Angioplasty

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence Of Transient Ischemic Attack In Young People Favorable Reimbursement Policies
      • 3.2.2. Guide Wire Assisted Surgery In Elderly Population
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled Professional and Awareness
    • 3.4. Market Trends
      • 3.4.1. New Advancements In Catheterization Devices and Telemedicine
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transient Ischemic Attack, by End Users, Age Group, Diagnosis Type, Treatment and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Transient Ischemic Attack (Value)
      • 5.2.1. Global Transient Ischemic Attack by: End Users (Value)
        • 5.2.1.1. Hospitals & Clinics
        • 5.2.1.2. Diagnostic Centers
        • 5.2.1.3. Research Laboratories
      • 5.2.2. Global Transient Ischemic Attack by: Age Group (Value)
        • 5.2.2.1. 0–18 years
        • 5.2.2.2. 19–40 years
        • 5.2.2.3. 41–60 years
        • 5.2.2.4. 60+ years
      • 5.2.3. Global Transient Ischemic Attack by: Diagnosis Type (Value)
        • 5.2.3.1. Imaging Techniques
        • 5.2.3.2. Computed Tomography (Ct) Scan
        • 5.2.3.3. Carotid Duplex Scanning
        • 5.2.3.4. Magnetic Resonance Imaging
        • 5.2.3.5. Echocardiography
        • 5.2.3.6. Arteriography
      • 5.2.4. Global Transient Ischemic Attack Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Transient Ischemic Attack: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Boston Scientific Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cardinal Health, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GE Healthcare (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medtronic plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co. Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens Healthineers AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LivaNova PLC (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cigna (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Novartis AG (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Pfizer Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Transient Ischemic Attack Sale, by End Users, Age Group, Diagnosis Type, Treatment and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Transient Ischemic Attack (Value)
      • 7.2.1. Global Transient Ischemic Attack by: End Users (Value)
        • 7.2.1.1. Hospitals & Clinics
        • 7.2.1.2. Diagnostic Centers
        • 7.2.1.3. Research Laboratories
      • 7.2.2. Global Transient Ischemic Attack by: Age Group (Value)
        • 7.2.2.1. 0–18 years
        • 7.2.2.2. 19–40 years
        • 7.2.2.3. 41–60 years
        • 7.2.2.4. 60+ years
      • 7.2.3. Global Transient Ischemic Attack by: Diagnosis Type (Value)
        • 7.2.3.1. Imaging Techniques
        • 7.2.3.2. Computed Tomography (Ct) Scan
        • 7.2.3.3. Carotid Duplex Scanning
        • 7.2.3.4. Magnetic Resonance Imaging
        • 7.2.3.5. Echocardiography
        • 7.2.3.6. Arteriography
      • 7.2.4. Global Transient Ischemic Attack Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transient Ischemic Attack: by End Users(USD Million)
  • Table 2. Transient Ischemic Attack Hospitals & Clinics , by Region USD Million (2018-2023)
  • Table 3. Transient Ischemic Attack Diagnostic Centers , by Region USD Million (2018-2023)
  • Table 4. Transient Ischemic Attack Research Laboratories , by Region USD Million (2018-2023)
  • Table 5. Transient Ischemic Attack: by Age Group(USD Million)
  • Table 6. Transient Ischemic Attack 0–18 years , by Region USD Million (2018-2023)
  • Table 7. Transient Ischemic Attack 19–40 years , by Region USD Million (2018-2023)
  • Table 8. Transient Ischemic Attack 41–60 years , by Region USD Million (2018-2023)
  • Table 9. Transient Ischemic Attack 60+ years , by Region USD Million (2018-2023)
  • Table 10. Transient Ischemic Attack: by Diagnosis Type(USD Million)
  • Table 11. Transient Ischemic Attack Imaging Techniques , by Region USD Million (2018-2023)
  • Table 12. Transient Ischemic Attack Computed Tomography (Ct) Scan , by Region USD Million (2018-2023)
  • Table 13. Transient Ischemic Attack Carotid Duplex Scanning , by Region USD Million (2018-2023)
  • Table 14. Transient Ischemic Attack Magnetic Resonance Imaging , by Region USD Million (2018-2023)
  • Table 15. Transient Ischemic Attack Echocardiography , by Region USD Million (2018-2023)
  • Table 16. Transient Ischemic Attack Arteriography , by Region USD Million (2018-2023)
  • Table 17. South America Transient Ischemic Attack, by Country USD Million (2018-2023)
  • Table 18. South America Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 19. South America Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 20. South America Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 21. South America Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 22. Brazil Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 23. Brazil Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 24. Brazil Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 25. Brazil Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 26. Argentina Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 27. Argentina Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 28. Argentina Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 29. Argentina Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 30. Rest of South America Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 31. Rest of South America Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 32. Rest of South America Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 33. Rest of South America Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 34. Asia Pacific Transient Ischemic Attack, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 36. Asia Pacific Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 37. Asia Pacific Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 38. Asia Pacific Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 39. China Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 40. China Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 41. China Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 42. China Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 43. Japan Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 44. Japan Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 45. Japan Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 46. Japan Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 47. India Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 48. India Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 49. India Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 50. India Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 51. South Korea Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 52. South Korea Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 53. South Korea Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 54. South Korea Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 55. Taiwan Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 56. Taiwan Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 57. Taiwan Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 58. Taiwan Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 59. Australia Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 60. Australia Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 61. Australia Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 62. Australia Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 67. Europe Transient Ischemic Attack, by Country USD Million (2018-2023)
  • Table 68. Europe Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 69. Europe Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 70. Europe Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 71. Europe Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 72. Germany Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 73. Germany Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 74. Germany Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 75. Germany Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 76. France Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 77. France Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 78. France Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 79. France Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 80. Italy Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 81. Italy Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 82. Italy Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 83. Italy Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 84. United Kingdom Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 85. United Kingdom Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 86. United Kingdom Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 87. United Kingdom Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 88. Netherlands Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 89. Netherlands Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 90. Netherlands Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 91. Netherlands Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 92. Rest of Europe Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 93. Rest of Europe Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 94. Rest of Europe Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 95. Rest of Europe Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 96. MEA Transient Ischemic Attack, by Country USD Million (2018-2023)
  • Table 97. MEA Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 98. MEA Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 99. MEA Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 100. MEA Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 101. Middle East Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 102. Middle East Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 103. Middle East Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 104. Middle East Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 105. Africa Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 106. Africa Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 107. Africa Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 108. Africa Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 109. North America Transient Ischemic Attack, by Country USD Million (2018-2023)
  • Table 110. North America Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 111. North America Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 112. North America Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 113. North America Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 114. United States Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 115. United States Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 116. United States Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 117. United States Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 118. Canada Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 119. Canada Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 120. Canada Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 121. Canada Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 122. Mexico Transient Ischemic Attack, by End Users USD Million (2018-2023)
  • Table 123. Mexico Transient Ischemic Attack, by Age Group USD Million (2018-2023)
  • Table 124. Mexico Transient Ischemic Attack, by Diagnosis Type USD Million (2018-2023)
  • Table 125. Mexico Transient Ischemic Attack, by Treatment USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Transient Ischemic Attack: by End Users(USD Million)
  • Table 139. Transient Ischemic Attack Hospitals & Clinics , by Region USD Million (2025-2030)
  • Table 140. Transient Ischemic Attack Diagnostic Centers , by Region USD Million (2025-2030)
  • Table 141. Transient Ischemic Attack Research Laboratories , by Region USD Million (2025-2030)
  • Table 142. Transient Ischemic Attack: by Age Group(USD Million)
  • Table 143. Transient Ischemic Attack 0–18 years , by Region USD Million (2025-2030)
  • Table 144. Transient Ischemic Attack 19–40 years , by Region USD Million (2025-2030)
  • Table 145. Transient Ischemic Attack 41–60 years , by Region USD Million (2025-2030)
  • Table 146. Transient Ischemic Attack 60+ years , by Region USD Million (2025-2030)
  • Table 147. Transient Ischemic Attack: by Diagnosis Type(USD Million)
  • Table 148. Transient Ischemic Attack Imaging Techniques , by Region USD Million (2025-2030)
  • Table 149. Transient Ischemic Attack Computed Tomography (Ct) Scan , by Region USD Million (2025-2030)
  • Table 150. Transient Ischemic Attack Carotid Duplex Scanning , by Region USD Million (2025-2030)
  • Table 151. Transient Ischemic Attack Magnetic Resonance Imaging , by Region USD Million (2025-2030)
  • Table 152. Transient Ischemic Attack Echocardiography , by Region USD Million (2025-2030)
  • Table 153. Transient Ischemic Attack Arteriography , by Region USD Million (2025-2030)
  • Table 154. South America Transient Ischemic Attack, by Country USD Million (2025-2030)
  • Table 155. South America Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 156. South America Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 157. South America Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 158. South America Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 159. Brazil Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 160. Brazil Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 161. Brazil Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 162. Brazil Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 163. Argentina Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 164. Argentina Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 165. Argentina Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 166. Argentina Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 167. Rest of South America Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 168. Rest of South America Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 169. Rest of South America Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 170. Rest of South America Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 171. Asia Pacific Transient Ischemic Attack, by Country USD Million (2025-2030)
  • Table 172. Asia Pacific Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 173. Asia Pacific Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 174. Asia Pacific Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 175. Asia Pacific Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 176. China Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 177. China Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 178. China Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 179. China Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 180. Japan Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 181. Japan Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 182. Japan Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 183. Japan Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 184. India Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 185. India Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 186. India Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 187. India Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 188. South Korea Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 189. South Korea Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 190. South Korea Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 191. South Korea Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 192. Taiwan Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 193. Taiwan Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 194. Taiwan Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 195. Taiwan Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 196. Australia Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 197. Australia Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 198. Australia Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 199. Australia Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 204. Europe Transient Ischemic Attack, by Country USD Million (2025-2030)
  • Table 205. Europe Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 206. Europe Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 207. Europe Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 208. Europe Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 209. Germany Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 210. Germany Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 211. Germany Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 212. Germany Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 213. France Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 214. France Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 215. France Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 216. France Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 217. Italy Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 218. Italy Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 219. Italy Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 220. Italy Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 221. United Kingdom Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 222. United Kingdom Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 223. United Kingdom Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 224. United Kingdom Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 225. Netherlands Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 226. Netherlands Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 227. Netherlands Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 228. Netherlands Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 229. Rest of Europe Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 230. Rest of Europe Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 231. Rest of Europe Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 232. Rest of Europe Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 233. MEA Transient Ischemic Attack, by Country USD Million (2025-2030)
  • Table 234. MEA Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 235. MEA Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 236. MEA Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 237. MEA Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 238. Middle East Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 239. Middle East Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 240. Middle East Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 241. Middle East Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 242. Africa Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 243. Africa Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 244. Africa Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 245. Africa Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 246. North America Transient Ischemic Attack, by Country USD Million (2025-2030)
  • Table 247. North America Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 248. North America Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 249. North America Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 250. North America Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 251. United States Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 252. United States Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 253. United States Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 254. United States Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 255. Canada Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 256. Canada Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 257. Canada Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 258. Canada Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 259. Mexico Transient Ischemic Attack, by End Users USD Million (2025-2030)
  • Table 260. Mexico Transient Ischemic Attack, by Age Group USD Million (2025-2030)
  • Table 261. Mexico Transient Ischemic Attack, by Diagnosis Type USD Million (2025-2030)
  • Table 262. Mexico Transient Ischemic Attack, by Treatment USD Million (2025-2030)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transient Ischemic Attack: by End Users USD Million (2018-2023)
  • Figure 5. Global Transient Ischemic Attack: by Age Group USD Million (2018-2023)
  • Figure 6. Global Transient Ischemic Attack: by Diagnosis Type USD Million (2018-2023)
  • Figure 7. South America Transient Ischemic Attack Share (%), by Country
  • Figure 8. Asia Pacific Transient Ischemic Attack Share (%), by Country
  • Figure 9. Europe Transient Ischemic Attack Share (%), by Country
  • Figure 10. MEA Transient Ischemic Attack Share (%), by Country
  • Figure 11. North America Transient Ischemic Attack Share (%), by Country
  • Figure 12. Global Transient Ischemic Attack share by Players 2023 (%)
  • Figure 13. Global Transient Ischemic Attack share by Players (Top 3) 2023(%)
  • Figure 14. Global Transient Ischemic Attack share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 17. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 18. Boston Scientific Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Boston Scientific Corporation (United States) Revenue: by Geography 2023
  • Figure 20. Cardinal Health, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Cardinal Health, Inc. (United States) Revenue: by Geography 2023
  • Figure 22. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 23. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 24. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Medtronic plc (Ireland) Revenue: by Geography 2023
  • Figure 26. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Siemens Healthineers AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. Siemens Healthineers AG (Germany) Revenue: by Geography 2023
  • Figure 30. LivaNova PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. LivaNova PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 32. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 34. Cigna (United States) Revenue, Net Income and Gross profit
  • Figure 35. Cigna (United States) Revenue: by Geography 2023
  • Figure 36. Novartis AG (United States) Revenue, Net Income and Gross profit
  • Figure 37. Novartis AG (United States) Revenue: by Geography 2023
  • Figure 38. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 40. Global Transient Ischemic Attack: by End Users USD Million (2025-2030)
  • Figure 41. Global Transient Ischemic Attack: by Age Group USD Million (2025-2030)
  • Figure 42. Global Transient Ischemic Attack: by Diagnosis Type USD Million (2025-2030)
  • Figure 43. South America Transient Ischemic Attack Share (%), by Country
  • Figure 44. Asia Pacific Transient Ischemic Attack Share (%), by Country
  • Figure 45. Europe Transient Ischemic Attack Share (%), by Country
  • Figure 46. MEA Transient Ischemic Attack Share (%), by Country
  • Figure 47. North America Transient Ischemic Attack Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Boston Scientific Corporation (United States)
  • Cardinal Health, Inc. (United States)
  • GE Healthcare (United States)
  • Medtronic plc (Ireland)
  • Merck & Co. Inc. (United States)
  • Siemens Healthineers AG (Germany)
  • LivaNova PLC (United Kingdom)
  • Bayer AG (Germany)
  • Cigna (United States)
  • Novartis AG (United States)
  • Pfizer Inc. (United States)
Additional players considered in the study are as follows:
Daiichi Sankyo Co., Ltd. (Japan) , electroCore, Inc. (United States) , Eli Lilly and Company (United States) , Novo Nordisk A/S (Denmark) , Sanofi SA (France) , Stryker Corporation (United States) , Terumo Corporation (Japan) , Zocere, Inc. (Mexico)
Select User Access Type

Key Highlights of Report


Jan 2024 226 Pages 96 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
global Transient Ischemic Attack Market Quantitative research analysis
global Transient Ischemic Attack Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Abbott Laboratories (United States), Boston Scientific Corporation (United States), Cardinal Health, Inc. (United States), GE Healthcare (United States), Medtronic plc (Ireland), Merck & Co. Inc. (United States), Siemens Healthineers AG (Germany), LivaNova PLC (United Kingdom), Bayer AG (Germany), Cigna (United States), Novartis AG (United States) and Pfizer Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"New Advancements In Catheterization Devices and Telemedicine" is seen as one of major influencing trends for Transient Ischemic Attack Market during projected period 2023-2030.
The Transient Ischemic Attack market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About global Transient Ischemic Attack Market Report?

Have a Query? Click Here

Other Related Reports

Limb Girdle Muscular Dystrophy Comprehensive Study by Type (LGMD1, LGMD2), Application (Hospitals, Clinics, Others), Treatment Type (Occupational Therapy, Respiratory Therapy, Speech Therapy), Diagno...
$ 3350
Hypereosinophilic Syndrome Comprehensive Study by Treatment (Corticosteroids, Biological Therapy, Chemotherapy, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centres), Distribution Chan...
$ 3750
Niemann-Pick Disease Comprehensive Study by Type (Niemann-Pick Type A, Niemann-Pick Type B, Niemann-Pick Type C), Application (Genetic Testing and Diagnosis, Therapeutic Research), Treatment (Bone Ma...
$ 3650
Gliosarcoma Comprehensive Study by Type (Primary Gliosarcoma, Secondary Gliosarcoma), Treatment (Surgery, Radiation, Chemotherapy, Immunotherapy Drugs), End-users (Hospitals, Clinics, Ambulatory Surg...
$ 3450
Localized Scleroderma Comprehensive Study by Type (Morphea, Linear Scleroderma), Treatment (Creams, Ointments, Phototherapy, Steroids, Medication), End-users (Hospitals, Clinics, Others), Distributio...
$ 3650
Partial Epilepsy Comprehensive Study by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers), End User (Adul...
$ 3500